Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis

Mariadelfina Molinaro,1 Paola Morelli,2 Manuela De Gregori,1,3,4 Simona De Gregori,1 Ilaria Giardini,1 Federica Tordato,2 Vincenzina Monzillo,5,6 Daria Pocaterra,2 Erminia Casari7 1Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, 2Infectious Diseases U...

Full description

Bibliographic Details
Main Authors:	Molinaro M, Morelli P, De Gregori M, De Gregori S, Giardini I, Tordato F, Monzillo V, Pocaterra D, Casari E
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-09-01
Series:	Infection and Drug Resistance
Subjects:	Pan- resistant meningitis Pseudomonas aeruginosa amikacin
Online Access:	https://www.dovepress.com/efficacy-of-intraventricular-amikacin-treatment-in-pan-resistant-pseud-peer-reviewed-article-IDR

Similar Items

The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection
by: Mohsen Yazdanian, et al.
Published: (2023-03-01)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
by: Yuhang Wang, et al.
Published: (2022-10-01)

Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of Pseudomonas aeruginosa
by: Hai Yang, et al.
Published: (2023-12-01)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
by: Xi-kang Tang, et al.
Published: (2022-03-01)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
by: Minyon L. Avent, et al.
Published: (2022-06-01)

Successful Treatment of Serious Meningitis Caused by Extremely Carbapenem-Resistant Enterobacter cloacae (MIC≥16mg/L) with i.v. Meropenem and i.v. Amikacin Plus Intraventricular Amikacin
by: He Z, et al.
Published: (2019-12-01)

Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant <i>Pseudomonas aeruginosa</i>
by: Sara Mahmoud Farhan, et al.
Published: (2021-11-01)

Intrathecal use of amikacin: a case report
by: L. Barrou, et al.

The clinical characteristics of adult bacterial meningitis caused by non-Pseudomonas (Ps.) aeruginosa Pseudomonas species: A clinical comparison with Ps. aeruginosa meningitis
by: Chi-Ren Huang, et al.
Published: (2018-01-01)

Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients
by: Hideo Kato, et al.
Published: (2021-01-01)

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
by: Ana Motos, et al.
Published: (2023-02-01)

Enhanced effect of Amikacin in conjugation with gold nanopartcles as a carrier to kill Pseudomonas aeruginosa
by: Afsaneh Emameian, et al.
Published: (2020-12-01)

Combination Therapy of Polymyxin B and Amikacin for Community-Acquired Pseudomonas aeruginosa Pneumonia with MODS in a Previously Healthy Patient: A Case Report
by: Wang J, et al.
Published: (2021-07-01)

Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
by: Antoni Torres, et al.
Published: (2018-12-01)

Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues
by: Styliani Xiroudaki, et al.
Published: (2021-01-01)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01)

Clinical Pharmacokinetics of Amikacin in Neonates
by: Gian Maria Pacifici, et al.
Published: (2017-02-01)

Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia
by: Sameh Seyam, et al.
Published: (2022-06-01)

Intrathecal Injection of Polymyxin B in a Child with Meningitis Caused by Carbapenem-Resistant Pseudomonas aeruginosa: A Case Report and Literature Review
by: Wu M, et al.
Published: (2024-01-01)

Case Report: A Domestic Sponge Brush Used to Clean a Milk Feeding Bottle: The Source of Neonatal Meningitis Caused by Pseudomonas aeruginosa
by: Shinsuke Mizuno, et al.
Published: (2021-09-01)

Study of the antimicrobial effect of Amikacin encapsulated in Mesoporous Silica nanoparticles against Pseudomonas aeruginosa and Staphylococcus aureus
by: Somayeh Hosseini khomeirani, et al.
Published: (2017-04-01)

Protective effect of creatine on amikacin-induced ototoxicity
by: Emre Apaydın, et al.
Published: (2022-09-01)

The Direction of the Antibacterial Effect of Rutin Hydrate and Amikacin
by: Maria Miklasińska-Majdanik, et al.
Published: (2023-09-01)

Effect of mannitol on the pharmacokinetics of amikacin in wistar rats
by: Hugo Juárez Olguín, et al.
Published: (2009-08-01)

Intraperitoneal Amikacine Provoked Perceptive Deafness in CAPD - Continuous Ambulatory Peritoneal Dialysis Patient
by: Lutfi Zylbeari, et al.
Published: (2020-07-01)

Review on Population Pharmacokinetics of Amikacin in Paediatrics
by: Keerthana Chandrasekar, et al.
Published: (2022-12-01)

Inducible Resistance to Amikacin in Mycobacterium abscessus Isolated in Beijing, China
by: Zhang Z, et al.
Published: (2022-04-01)

The Role of Aspirin as Otoprotective Agent in Patients Receiving Amikacin Therapy
by: Estabraq M. Mahdi
Published: (2011-06-01)

Standard Multiple and Single Daily Dosing of Amikacin in Premature Infants
by: Arash Bordbar, et al.
Published: (2017-12-01)

Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa
by: Yixin Kang, et al.
Published: (2023-06-01)

Amikacin: Uses, Resistance, and Prospects for Inhibition
by: Maria S. Ramirez, et al.
Published: (2017-12-01)

Heteroresistance to Amikacin in Carbapenem-Resistant Klebsiella pneumoniae Strains
by: Feiyang Zhang, et al.
Published: (2021-12-01)

Off-Label Use of Ceftolozane/Tazobactam for the Successful Treatment of Healthcare-Associated Meningitis Caused by Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> in a Polytraumatized Patient—A Case Report
by: Simon Dubler, et al.
Published: (2022-08-01)

Protective Effect of Pentoxifylline on Amikacin-Induced Renal Toxicity in Mice
by: Mohammad Shokati Sayad, et al.
Published: (2023-10-01)

Effect of amikacin, cephalothin, clindamycin and vancomycin on in vitro fibroblast growth
by: Fernanda Timm Seabra Souza, et al.
Published: (2004-01-01)

Antibiotic therapy by intrathecal or intraventricular approach for postsurgical meningitis or ventriculitis: a systematic review and meta-analysis
by: William A. Florez-Perdomo, et al.
Published: (2023-05-01)

Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients
by: Maria Aquino, et al.
Published: (2023-02-01)

Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence
by: Joy E. Gibson, et al.
Published: (2024-02-01)

MUTAGENESIS OF A Pseudomonos aeruginosa By USING NITROUS ACID
by: Khalaf Jasim Mohammed Al-Dolaimi
Published: (2012-06-01)

Plasma concentration and eGFR in preterm and term neonates receiving gentamicin or successive amikacin therapy
by: Bonifasius Siyuka Singu, et al.
Published: (2023-01-01)